Skip to main content

Table 3 Effect of iron deficiency treatment (scheduled subgroup analysis)

From: Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial

 

n

Patients with ID treated in hepcidin arm (n = 53)

n

Patients with ID not treated in control arm (n = 102)

p

Primary outcome

     

Post-ICU LOS (days)

53

42 (16; 90)

102

29 (11; 90)

0.37

Secondary outcomes

     

Number of days alive at home at day 90

53

50 (0; 76)

102

61 (0; 82)

0.21

Day 15 visit

     

Day 15 Hb (g/dL)

40

10.7 ± 1.6

59

10.4 ± 1.4

0.24

Day 15 hepcidin (µg/L)

19

35.7 (23.0; 53.7)

31

18.0 (7.6; 44.0)

0.04

Day 30 visit

     

Fatigue (scale 1–10)

39

5.0 (3.0; 6.0)

61

6.0 (3.0; 7.0)

0.13

MFI-20

     

 General fatigue (score 9–45)

40

28 (22; 31)

63

26 (18; 30)

0.33

 Mental fatigue (score 6–30)

40

25 (20; 28)

63

25 (20; 28)

0.75

 Reduced activity (score 3–15)

40

8 (6;10)

63

8 (6;11)

0.66

 Reduced motivation (score 2–10)

40

8.(6;10)

63

8 (6; 10)

0.24

Mortality

     

Death at day 90

53

2 (3.8)

102

17 (16.7)

0.02

  1. Data are expressed as mean ± SD, median(Q1;Q3) or n(%). We compared the outcomes of patient with iron deficiency (ID, defined as an hepcidin concentration < 41 µg/L) treated in the hepcidin arm to the patients with ID not treated in the control arm
  2. Italics were used to indicate sub-headings in the tables and p-values
  3. ICU intensive care unit, LOS length of stay, MFI-20 multidimensional fatigue inventory, Hb hemoglobin
  4. * Absolute risk difference